Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(1.95)
# 3,143
Out of 5,245 analysts
51
Total ratings
40.43%
Success rate
-7.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Outperform | $95 → $91 | $34.04 | +167.33% | 2 | May 15, 2026 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $34 → $33 | $17.37 | +89.98% | 2 | May 15, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $1,007 → $1,059 | $806.46 | +31.31% | 6 | May 15, 2026 | |
| ABBV AbbVie | Maintains: Outperform | $236 → $235 | $215.70 | +8.95% | 8 | May 15, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $135 → $138 | $98.62 | +39.93% | 6 | May 7, 2026 | |
| KRYS Krystal Biotech | Maintains: Outperform | $295 → $300 | $299.45 | +0.18% | 2 | May 5, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Outperform | $20 → $18 | $9.24 | +94.81% | 1 | Apr 1, 2026 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $12 → $7 | $0.903 | +675.19% | 5 | Apr 1, 2026 | |
| DMRA Damora Therapeutics | Initiates: Outperform | $46 | $25.30 | +81.82% | 1 | Mar 25, 2026 | |
| EVMN Evommune | Initiates: Outperform | $40 | $22.87 | +74.90% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $21.55 | +201.69% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.56 | +220.51% | 1 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $15 → $6 | $3.65 | +64.38% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $16.80 | +911.90% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $4.22 | +373.93% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $4.52 | +386.73% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $3.56 | +180.90% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $101.32 | -40.78% | 1 | Oct 5, 2022 |
Vera Therapeutics
May 15, 2026
Maintains: Outperform
Price Target: $95 → $91
Current: $34.04
Upside: +167.33%
Dyne Therapeutics
May 15, 2026
Maintains: Outperform
Price Target: $34 → $33
Current: $17.37
Upside: +89.98%
argenx SE
May 15, 2026
Maintains: Outperform
Price Target: $1,007 → $1,059
Current: $806.46
Upside: +31.31%
AbbVie
May 15, 2026
Maintains: Outperform
Price Target: $236 → $235
Current: $215.70
Upside: +8.95%
Mirum Pharmaceuticals
May 7, 2026
Maintains: Outperform
Price Target: $135 → $138
Current: $98.62
Upside: +39.93%
Krystal Biotech
May 5, 2026
Maintains: Outperform
Price Target: $295 → $300
Current: $299.45
Upside: +0.18%
MeiraGTx Holdings
Apr 1, 2026
Maintains: Outperform
Price Target: $20 → $18
Current: $9.24
Upside: +94.81%
Jasper Therapeutics
Apr 1, 2026
Maintains: Outperform
Price Target: $12 → $7
Current: $0.903
Upside: +675.19%
Damora Therapeutics
Mar 25, 2026
Initiates: Outperform
Price Target: $46
Current: $25.30
Upside: +81.82%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $22.87
Upside: +74.90%
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $21.55
Upside: +201.69%
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.56
Upside: +220.51%
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $3.65
Upside: +64.38%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $16.80
Upside: +911.90%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.22
Upside: +373.93%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $4.52
Upside: +386.73%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $3.56
Upside: +180.90%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $101.32
Upside: -40.78%